Skip to main content
2024 State-of-the Art Clinical Symposium Main banner
Final Program


Schedule at a Glance
Back

CAR-T Cell Therapy: What the Rheumatologists Need to Know

Saturday, April 13, 2024
8:40 AM – 9:30 AM Central Time

    Moderator(s)

  • Sobia Hassan, MD, RhMSUS, MRCP

    RUSH University
    Chicago, IL, United States

    Disclosure(s): No financial relationships with ineligible companies to disclose

    • Speaker(s)

  • JM

    Javier Munoz

    Mayo Clinic
    Phoenix, AZ, United States

    Disclosure(s): No relevant disclosure to display

Chimeric antigen receptor (CAR) T-cells are currently FDA approved for patients with lymphoma, multiple myeloma, and acute lymphoblastic leukemia. CAR T-cells have revolutionized the therapeutic landscape for Hematologic malignancies. The option of using CAR T-cells for non-cancer related conditions (including autoimmune diseases) is under active investigation in clinical trials. In this session, we will go over the basics of CAR T-cells. To develop CAR T-cells in autoimmune conditions via clinical trials, we will draft a roadmap to apply all the knowledge that we have learned using CAR T-cells in lymphoma.

Learning Objectives:

  • Summarize the current FDA approved indications for CAR T-cells
  • Recognize the potential use of CAR T-cells for autoimmune diseases under investigation via clinical trials
  • Describe possible toxicity associated with CAR T-cells

Presentations:

  • 8:40 AM – 9:20 AM Central Time
    CAR-T Cell Therapy: What the Rheumatologists Need to Know

    Speaker: Javier Munoz – Mayo Clinic

  • 9:20 AM – 9:30 AM Central Time
    Q&A

    Q&A Moderator: Sobia Hassan, MD, RhMSUS, MRCP – RUSH University

    Q&A Presenter: Javier Munoz – Mayo Clinic